首页> 外文期刊>Respiration: International Review of Thoracic Diseases >Interferon-alphacon-1 treatment of three patients with severe glucocorticoid-dependent asthma. Effect on disease control and systemic glucocorticosteroid dose.
【24h】

Interferon-alphacon-1 treatment of three patients with severe glucocorticoid-dependent asthma. Effect on disease control and systemic glucocorticosteroid dose.

机译:干扰素-αcon-1治疗三例严重糖皮质激素依赖型哮喘。对疾病控制和全身糖皮质激素剂量的影响。

获取原文
获取原文并翻译 | 示例
       

摘要

We report herein the therapeutic effect of interferon (IFN)-alphacon in three patients with severe persistent asthma and long-term oral glucocorticoid treatment. IFN-alphacon (9 microg) administered subcutaneously thrice a week over a period of more than 24 months led to a substantial clinical improvement with regard to the number of daily asthma attacks, nighttime disturbance, emergency visits and hospitalizations. In addition, lung function and exercise capacity improved. At the same time, treatment with IFN allowed discontinuation of the daily glucocorticoid dose in all patients for the first time in more than 8 years. Our findings suggest that IFN-alphacon leads to a significant clinical improvement while at the same time allowing reduction and discontinuation of the glucocorticoid treatment in severe persistent glucocorticoid-dependent asthma.
机译:我们在此报告干扰素(IFN)-αcon在三例严重持续性哮喘和长期口服糖皮质激素治疗的患者中的治疗效果。在超过24个月的时间内每周三次皮下注射IFN-αcon(9微克),导致每日哮喘发作,夜间干扰,紧急就诊和住院的次数大大改善。此外,肺功能和运动能力得到改善。同时,用IFN治疗可以在8年来首次中断所有患者的每日糖皮质激素剂量。我们的发现表明,IFN-αcon可以显着改善临床症状,同时在严重的持续性糖皮质激素依赖型哮喘中,可以减少和停用糖皮质激素治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号